Market Research Logo

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2016

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2016’, provides an overview of the Chemotherapy Induced Nausea and Vomiting pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting
  • The report reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chemotherapy Induced Nausea and Vomiting therapeutics and enlists all their major and minor projects
  • The report assesses Chemotherapy Induced Nausea and Vomiting therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Nausea and Vomiting Overview
Therapeutics Development
Pipeline Products for Chemotherapy Induced Nausea and Vomiting - Overview
Chemotherapy Induced Nausea and Vomiting - Therapeutics under Development by Companies
Chemotherapy Induced Nausea and Vomiting - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Chemotherapy Induced Nausea and Vomiting - Products under Development by Companies
Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development
Acacia Pharma Limited
Aphios Corporation
Astellas Pharma Inc.
Athenex, Inc.
Helsinn Healthcare S.A.
Heron Therapeutics, Inc.
INSYS Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
Nemus Bioscience, Inc.
RedHill Biopharma Ltd.
SoluBest Ltd.
Suda Ltd
Tesaro, Inc.
Therapix Biosciences Ltd
Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(netupitant + palonosetron hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(palonosetron hydrochloride + Pro-netupitant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APD-403 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aprepitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aprepitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FK-886 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
granisetron - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
granisetron ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
granisetron ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
granisetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LPI-1504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LPI-1505 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-1222 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
netupitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palmidrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rolapitant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chemotherapy Induced Nausea and Vomiting - Dormant Projects
Chemotherapy Induced Nausea and Vomiting - Discontinued Products
Chemotherapy Induced Nausea and Vomiting - Product Development Milestones
Featured News & Press Releases
Jun 23, 2016: TESARO Announces Rolapitant Data Presentations at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer
Jun 04, 2016: TESARO Provides Update on Rolapitant IV at ASCO Investor Briefing
May 18, 2016: TESARO Announces Two Abstracts on (VARUBI) Rolapitant to be Presented at the 2016 American Society of Clinical Oncology Annual Meeting
Apr 18, 2016: Heron Therapeutics Provides Update on FDA Review of SUSTOL NDA
Mar 23, 2016: TESARO Announces Validation of Marketing Authorisation Application for Oral Rolapitant by the European Medicines Agency
Mar 14, 2016: TESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug Administration
Mar 03, 2016: Heron Therapeutics Provides Update on SUSTOL (granisetron) Injection NDA
Feb 29, 2016: Heron Therapeutics Provides Update on SUSTOL NDA
Feb 01, 2016: Biologics Announces New Oncology Partnership
Jan 15, 2016: Heron Therapeutics Notified by FDA That It Will Not Take Action on SUSTOL New Drug Application by the PDUFA Date
Dec 15, 2015: Swissmedic Approves Akynzeo (netupitant/palonosetron) for use in the Prevention of Chemotherapy Induced Nausea and Vomiting in Switzerland
Nov 16, 2015: OPKO Licensee TESARO Announces the Launch of VARUBI (Rolapitant) in the United States
Nov 13, 2015: Helsinn Group and Eisai Announce Inclusion of AKYNZEO in American Society of Clinical Oncology Antiemetics Guid
Oct 14, 2015: Helsinn’s AKYNZEO (netupitant/palonosetron) nominated within the category “Best Pharmaceutical Agent of the Year” at The Galien Foundation Prix Award
Oct 14, 2015: Luxena Received FDA Orphan Drug Designation for LPI-1503
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Limited, H2 2016
Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corporation, H2 2016
Chemotherapy Induced Nausea and Vomiting - Pipeline by Astellas Pharma Inc., H2 2016
Chemotherapy Induced Nausea and Vomiting - Pipeline by Athenex, Inc., H2 2016
Chemotherapy Induced Nausea and Vomiting - Pipeline by Helsinn Healthcare S.A., H2 2016
Chemotherapy Induced Nausea and Vomiting - Pipeline by Heron Therapeutics, Inc., H2 2016
Chemotherapy Induced Nausea and Vomiting - Pipeline by INSYS Therapeutics, Inc., H2 2016
Chemotherapy Induced Nausea and Vomiting - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016
Chemotherapy Induced Nausea and Vomiting - Pipeline by Nemus Bioscience, Inc., H2 2016
Chemotherapy Induced Nausea and Vomiting - Pipeline by RedHill Biopharma Ltd., H2 2016
Chemotherapy Induced Nausea and Vomiting - Pipeline by SoluBest Ltd., H2 2016
Chemotherapy Induced Nausea and Vomiting - Pipeline by Suda Ltd, H2 2016
Chemotherapy Induced Nausea and Vomiting - Pipeline by Tesaro, Inc., H2 2016
Chemotherapy Induced Nausea and Vomiting - Pipeline by Therapix Biosciences Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H2 2016
Chemotherapy Induced Nausea and Vomiting - Dormant Projects (Contd..1), H2 2016
Chemotherapy Induced Nausea and Vomiting - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report